Inovio Pharmaceuticals【INO】銘柄情報

	リアルタイム株価	レベル2
Forex

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

4.19

買値

4.00

売値

4.27

出来高

0.00 日の範囲 0.00

3.8699 52 週間の範囲 14.748

時価総額

109.359M

前日終値

4.19

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

332,787

発行済株式数

26,099,991

配当利回り

PER

-0.81

1 株当たり利益 (EPS)

-5.18

歳入

832k

純利益

-135.12M

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and... Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. 詳細を表示

セクター

Surgical,med Instr,apparatus

業界

Surgical,med Instr,apparatus

ウェブサイト

www.inovio.com

本社

Wilmington, Delaware, USA

設立

Inovio Pharmaceuticals Inc New is listed in the Surgical,med Instr,apparatus sector of the ナスダック市場 with ticker INO. The last closing price for Inovio Pharmaceuticals was US$4.19. Over the last year, Inovio Pharmaceuticals shares have traded in a share price range of US$ 3.8699 to US$ 14.748.

Inovio Pharmaceuticals currently has 26,099,991 shares in issue. The market capitalisation of Inovio Pharmaceuticals is US$109.36 million. Inovio Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.81.

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING, Pa., Nov. 14, 2024 New immunology data for INO-3107 supporting proposed mechanism...

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.11	2.69607843137	4.08	4.27	4	416081	4.10584303	CS
4	-1.11	-20.9433962264	5.3	5.77	3.8699	409078	4.6193799	CS
12	-2.31	-35.5384615385	6.5	7	3.8699	332787	5.35910193	CS
26	-6.02	-58.9618021548	10.21	12.33	3.8699	343977	7.35418487	CS
52	-0.5332	-11.2889566396	4.7232	14.748	3.8699	1011311	7.87795562	CS
156	-87.382	-95.4243655266	91.572	91.92	3.8699	4032142	21.03921726	CS
260	-25.81	-86.0333333333	30	426	3.8699	9039733	122.83809247	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
BSLKBolt Projects Holdings Inc	US$ 1.06 (258.11%)	16.46M
PGHLPrimega Group Holdings Ltd	US$ 2.68 (62.42%)	15.03M
EPRXEupraxia Pharmaceuticals Inc	US$ 5.00 (44.93%)	287
BMRABiomerica Inc	US$ 0.4656 (44.55%)	8.91M
NBTBNBT Bancorp Inc	US$ 63.24 (26.28%)	12
APLTApplied Therapeutics Inc	US$ 2.46 (-71.30%)	2.31M
DAIOData I O Corp	US$ 1.89 (-29.74%)	21
RCKYRocky Brands Inc	US$ 17.04 (-22.09%)	12
PKOHPark Ohio Holdings Corporation	US$ 25.00 (-21.97%)	456
KALVKalVista Pharmaceuticals Inc	US$ 8.01 (-20.61%)	3
BSLKBolt Projects Holdings Inc	US$ 1.06 (258.11%)	16.49M
PGHLPrimega Group Holdings Ltd	US$ 2.70 (63.64%)	15.05M
LGHLLion Group Holding Ltd	US$ 0.2063 (17.62%)	11.61M
BMRABiomerica Inc	US$ 0.4641 (44.09%)	8.92M
RGTIRigetti Computing Inc	US$ 2.60 (8.33%)	5.02M